Stem Cell Banking Market Analysis | 2022-2028

Market Insights

The Stem Cell Banking Market was estimated at US$ 4.81 billion in 2021 and is expected to grow at a CAGR of 15.35% during 2022-2028 to reach US$ 15.56 billion in 2028.

Wish to get a free sample? Register here

What is a stem cell?

Stem cells can develop into any type of body tissue or organ. In addition to bone marrow, stem cells are also present in fetal tissues, baby teeth, fat, human embryos, hair follicles, muscle, and blood. Cord blood, however, is a reliable source of stem cells. Due to several benefits, such as their effectiveness in transplants due to lower risks of immunological rejection during the transfusion, stem cells from cord blood are chosen. The need for stem cell banking is rising as a result of the many ways that stem cells are being used, such as in the treatment of cancer and other disorders. These stem cells are taken from people and stored for potential use.

Market Dynamics

Over the forecast period, the global stem cell banking market's expansion is anticipated to be constrained by the high cost of stem cell banking. Because they are pricey, not everyone can afford stem cell preservation treatments. For instance, the private cord blood bank Americord Registry LLC claims that their standard fee ranges from USD 3,299 to USD 6,599 for the collection and 20-year storage of cord blood.

The use of placental stem cells in clinical settings has increased as it has been demonstrated that these cells have remarkable therapeutic properties in vivo, including anti-oxidant, anti-microbial, anti-inflammatory, pain reduction, hair growth promotion, health improvement, cellular proliferation, tissue regeneration, and wound healing properties. Placental stem cells have the potential to treat illnesses or rare diseases for which there are few effective treatments. These cells, sometimes referred to as the body's "master cells," can evolve into the brain, blood bones, and all the organs. These could be used to treat a variety of illnesses and ailments since they can repair, restore, replace, and regenerate cells. The treatment is very effective in treating conditions such as Alzheimer's disease.

Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:

• The Medical Products Agency granted Xintela approval in July 2022 for clinical Phase I/IIa research using XSTEM in patients with venous leg ulcers that are challenging to heal. Mesenchymal stem cells that have been quality-assured and integrin 101-selected makeup XSTEM, which is created in Xintela's own GMP facility. Twelve patients with venous leg ulcers that are challenging to heal will receive either XSTEM or a placebo in the clinical study, which will be conducted in conjunction with Professor Folke Sjöberg and his team at the University Hospital in Linköping. To assess the safety and effectiveness of the wound healing process, XSTEM/placebo will be administered to the wounds, and the patients will be monitored for 10 weeks. After the summer, the study will begin, and preliminary findings are anticipated by the end of 2022.

Segments Analysis

Key Players

The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the stem cell banking market:

• BrainStorm Cell Limited
• Caladrius Biosciences, Inc.
• Celgene Corporation
• Cord Blood Registry (CBR) Systems
• Cordlife Group Limited
• Cryo-Cell International
• CryoHoldco 
• Cryo-Save
• Global Cord Blood Corporation
• LifeCell International
• Regrow Biosciences Pvt. Ltd.
• Smart Cells International
• StemCyte
• ViaCord
• Vita34 AG

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

Recent Developments

Stem cell banking is a highly competitive market. To remain competitive in this market, market participants are placing a lot of emphasis on mergers, expansions, and product approvals. Here are a few significant developments:

• In September 2022, three distinct dose levels of the stem cell product XSTEM were tested in Australia as part of Xintela's first-in-human trial (Phase I/IIa) for the treatment of knee osteoarthritis. The lowest dose level has now been administered to all patients. Xintela created and produces XSTEM, which is made up of allogeneic (donated) mesenchymal stem cells that have been integrin 101-selected. An injection of XSTEM is given to patients with moderate knee osteoarthritis (grade II–III). Up to 54 individuals at three different dose levels will be studied, and each patient will have an 18-month follow-up with a 6-month efficacy readout. The main objective is to demonstrate the safety of XSTEM while also examining early efficacy indicators such as decreased joint cartilage degradation, regrowth of damaged cartilage, and enhanced joint function. Early efficacy results are anticipated in 2023, while initial safety data are anticipated before the end of this year
• Cryo-Cell International, Inc., the first private cord blood bank in the world to extract and preserve stem cells, and Duke University have collaborated under a license agreement that was signed in February 2021. The agreement gives Cryo-Cell access to exclusive procedures and legal information on Duke-developed cord blood and cord tissue
• American CryoStem Corporation, a global licensor, pioneer in autologous cellular processing and therapies, and clinical-stage biotechnology business, entered into a contract with BioTherapeutic Labs Corp. (BTL), an FDA-registered manufacturer of umbilical cord tissue, in February 2021. To deliver umbilical cord cells under its previously publicized "CRADA" partnership with the Biomedical Research Laboratory in Bethesda, Maryland, and for upcoming IND applications, CRYO will enhance cell recovery from the umbilical cord. The Agreement calls for BTL to market CRYO's goods and services as well as joint R&D work on protocols that use both BTL's human umbilical cord-derived product lines and ATCell autologous mesenchymal stem cells from CRYO. For usage in its ATCell manufacturing, product development, and end-to-end CryoStem Platform Technology. the businesses intend to validate and standardize the umbilical cord acellular suspension product.
• Cryo-Cell International, Inc. and Duke University signed a patent option agreement in June 2020. The six-month exclusive option contract offers Cryo-Cell the right to choose whether to buy a license to produce and market goods using Dr. Joanne Kurtzberg's patents.